CAM-DR: Mechanisms, Roles and Clinical Application in Tumors.
CAM-DR
hematologic malignancies
inhibitors
signaling pathways
tumor microenvironment
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
21
04
2021
accepted:
08
06
2021
entrez:
23
7
2021
pubmed:
24
7
2021
medline:
24
7
2021
Statut:
epublish
Résumé
Despite the continuous improvement of various therapeutic techniques, the overall prognosis of tumors has been significantly improved, but malignant tumors in the middle and advanced stages still cannot be completely cured. It is now evident that cell adhesion-mediated resistance (CAM-DR) limits the success of cancer therapies and is a great obstacle to overcome in the clinic. The interactions between tumor cells and extracellular matrix (ECM) molecules or adjacent cells may play a significant role in initiating the intracellular signaling pathways that are associated with cell proliferation, survival upon binding to their ligands. Recent studies illustrate that these adhesion-related factors may contribute to the survival of cancer cells after chemotherapeutic therapy, advantageous to resistant cells to proliferate and develop multiple mechanisms of drug resistance. In this review, we focus on the molecular basis of these interactions and the main signal transduction pathways that are involved in the enhancement of the cancer cells' survival. Furthermore, therapies targeting interactions between cancer cells and their environment to enhance drug response or prevent the emergence of drug resistance will also be discussed.
Identifiants
pubmed: 34295898
doi: 10.3389/fcell.2021.698047
pmc: PMC8290360
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
698047Informations de copyright
Copyright © 2021 Huang, Wang, Tang, Qin, Shen, He and Ju.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Semin Cancer Biol. 2015 Dec;35:145-53
pubmed: 26297892
Oncogene. 2006 Oct 26;25(50):6648-59
pubmed: 16702948
Leuk Res. 2016 Nov;50:104-111
pubmed: 27701018
J Biol Chem. 2013 Apr 5;288(14):10093-10099
pubmed: 23430739
Am J Cancer Res. 2015 Jan 15;5(2):830-43
pubmed: 25973320
Onco Targets Ther. 2018 Aug 13;11:4817-4827
pubmed: 30147333
Blood. 2011 Sep 29;118(13):3603-12
pubmed: 21803855
J Hematol Oncol. 2018 Jan 22;11(1):11
pubmed: 29357914
Leukemia. 2011 Jan;25(1):145-52
pubmed: 20966935
Leuk Res. 2020 Mar 9;92:106340
pubmed: 32182487
Semin Cancer Biol. 2015 Apr;31:65-75
pubmed: 25117005
Exp Cell Res. 2016 Aug 15;346(2):157-66
pubmed: 27397581
Blood Rev. 2006 Nov;20(6):333-42
pubmed: 16920238
Int J Oncol. 2014 Apr;44(4):1376-84
pubmed: 24452447
Cell Death Differ. 2006 Oct;13(10):1776-88
pubmed: 16410797
Adv Exp Med Biol. 2020;1277:143-158
pubmed: 33119871
Leukemia. 2009 Jan;23(1):170-7
pubmed: 18843286
Cancer Cell. 2007 Aug;12(2):131-44
pubmed: 17692805
Leuk Res. 2016 Aug;47:54-62
pubmed: 27258734
Sci Rep. 2016 Jan 05;6:18430
pubmed: 26728650
Cancer Sci. 2014 Jun;105(6):651-9
pubmed: 24703465
J Cell Physiol. 2019 Nov;234(11):19189-19198
pubmed: 30980400
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Cancer Res. 2006 Feb 15;66(4):2338-45
pubmed: 16489039
Cell Death Dis. 2021 Mar 12;12(3):266
pubmed: 33712559
Am J Hematol. 2017 Jan;92(1):7-11
pubmed: 27673440
Drug Des Devel Ther. 2018 Aug 21;12:2577-2590
pubmed: 30174412
Toxicol Appl Pharmacol. 2012 Mar 15;259(3):387-94
pubmed: 22310179
Cytokine. 2021 Jun;142:155479
pubmed: 33677228
Oncogene. 2011 Dec 8;30(49):4874-86
pubmed: 21625222
Drug Discov Today. 2021 Mar;26(3):724-739
pubmed: 33359624
Cancer Treat Rev. 2003 May;29 Suppl 1:11-9
pubmed: 12738239
Mol Cancer Ther. 2007 Jun;6(6):1774-84
pubmed: 17575106
Int J Biol Macromol. 2015 Nov;81:809-17
pubmed: 26341817
Stem Cell Res Ther. 2019 Nov 19;10(1):327
pubmed: 31744536
Int J Mol Sci. 2020 Aug 28;21(17):
pubmed: 32872365
Biochimie. 2015 Jun;113:17-25
pubmed: 25726913
Front Oncol. 2014 May 23;4:99
pubmed: 24904821
Glycobiology. 2018 Sep 1;28(9):648-655
pubmed: 29272415
Cancer Cell. 2007 Aug;12(2):95-7
pubmed: 17692798
J Control Release. 2010 Jul 14;145(2):91-101
pubmed: 20362019
Ann Hematol. 2017 May;96(5):847-858
pubmed: 28238095
Eur J Cancer. 2001 May;37(8):1041-52
pubmed: 11334731
Leuk Lymphoma. 2015 Jul;56(7):2153-61
pubmed: 25363345
Clin Cancer Res. 2011 Jan 1;17(1):193-200
pubmed: 21208908
Pediatr Clin North Am. 2015 Feb;62(1):47-60
pubmed: 25435111
Front Pharmacol. 2020 Sep 17;11:500137
pubmed: 33041787
Histopathology. 2013 Feb;62(3):414-20
pubmed: 23339364
Blood. 2010 Dec 9;116(24):5228-36
pubmed: 20841506
J Biomed Biotechnol. 2012;2012:157496
pubmed: 23093834
Stem Cells Dev. 2009 Oct;18(8):1235-42
pubmed: 19105599
Int J Biol Macromol. 2016 Oct;91:115-22
pubmed: 27189701
J Clin Invest. 2015 Oct 26;125(12):4375-90
pubmed: 26517694
Nat Rev Cancer. 2015 Jun;15(6):318-9
pubmed: 25998706
Sci Rep. 2019 Dec 19;9(1):19455
pubmed: 31857649
Curr Opin Pharmacol. 2020 Oct;54:36-43
pubmed: 32898723
Oncogene. 2008 Sep 4;27(39):5169-81
pubmed: 18469856
Blood. 2007 Sep 1;110(5):1631-8
pubmed: 17502456
Biochemistry (Mosc). 2001 Oct;66(10):1174-86
pubmed: 11736639
Cancer Sci. 2021 Mar;112(3):962-969
pubmed: 33377205
Life Sci. 2020 Nov 1;260:118411
pubmed: 32918978
Cold Spring Harb Perspect Med. 2018 Jul 2;8(7):
pubmed: 28963115
Clin Adv Hematol Oncol. 2020 Jul;18(7):413-422
pubmed: 32903253
Invasion Metastasis. 1996;16(2):65-72
pubmed: 9030241
J Biol Chem. 2012 Jul 13;287(29):24103-12
pubmed: 22511753
Clin Lymphoma Myeloma Leuk. 2018 May;18(5):311-320
pubmed: 29606369
Leuk Res. 2015 Dec;39(12):1428-36
pubmed: 26453405
Cancers (Basel). 2018 Dec 06;10(12):
pubmed: 30563275
Blood. 2018 Dec 6;132(23):2446-2455
pubmed: 30287523
Pathol Res Pract. 2019 Nov;215(11):152603
pubmed: 31540771
Blood. 2001 Sep 15;98(6):1897-903
pubmed: 11535527
Lancet Oncol. 2014 Mar;15(3):e108
pubmed: 24809089
J Immunol. 2002 Mar 1;168(5):2544-53
pubmed: 11859150
Oncogene. 2003 Apr 24;22(16):2417-21
pubmed: 12717418
Pharmacotherapy. 2018 Oct;38(10):1058-1067
pubmed: 30120858
Chemother Res Pract. 2012;2012:268681
pubmed: 22811904
Oncol Rep. 2016 Mar;35(3):1875-83
pubmed: 26718835
J Cancer Res Clin Oncol. 2016 Mar;142(3):561-72
pubmed: 26498772
Blood. 2018 Feb 22;131(8):877-887
pubmed: 29191916
Aging (Albany NY). 2020 Jun 10;12(11):11100-11115
pubmed: 32526706
Cancer Discov. 2019 Feb;9(2):210-219
pubmed: 30425037
Adv Drug Deliv Rev. 2013 Nov;65(13-14):1866-79
pubmed: 24120656
Blood. 2009 May 7;113(19):4604-13
pubmed: 19228923
Stem Cells. 2014 Apr;32(4):926-37
pubmed: 24357118
Drugs. 2018 Nov;78(17):1847-1853
pubmed: 30430368
J Pathol. 2020 Sep;252(1):29-40
pubmed: 32501543
Nat Cell Biol. 2015 Nov;17(11):1373-5
pubmed: 26515017
Cancer Res. 2018 Sep 1;78(17):4957-4970
pubmed: 29976575
Cancer Metastasis Rev. 2001;20(1-2):43-50
pubmed: 11831646
Blood. 2012 Mar 15;119(11):2590-4
pubmed: 22279054
Expert Rev Anticancer Ther. 2002 Aug;2(4):449-59
pubmed: 12647988
Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10538-43
pubmed: 10973491
BMC Cancer. 2019 Dec 30;19(1):1269
pubmed: 31888545
Blood. 2006 Jan 15;107(2):760-8
pubmed: 16189274
Clin Cancer Res. 2021 Apr 1;27(7):1974-1986
pubmed: 33355244
Exp Cell Res. 2015 Jul 15;335(2):216-23
pubmed: 26024773
Tumour Biol. 2017 Mar;39(3):1010428317694298
pubmed: 28351297
Leukemia. 2003 Jun;17(6):1175-82
pubmed: 12764386
Blood. 2011 Jun 9;117(23):6202-13
pubmed: 21474670
Am J Transl Res. 2019 Jul 15;11(7):4139-4150
pubmed: 31396324
Clin Cancer Res. 2013 Feb 1;19(3):586-97
pubmed: 23231952
Br J Haematol. 2017 Oct;179(1):36-49
pubmed: 28670693
Leuk Lymphoma. 2020 Sep;61(9):2068-2081
pubmed: 32449421
Leukemia. 2007 Jul;21(7):1521-31
pubmed: 17476277
Oncogene. 2001 Aug 16;20(36):4995-5004
pubmed: 11526484
Haematologica. 2009 Jan;94(1):78-86
pubmed: 19059936
Anticancer Drugs. 2000 Jul;11(6):407-17
pubmed: 11001381
Leuk Res. 2001 Oct;25(10):901-7
pubmed: 11532524
Clin Cancer Res. 2015 Apr 1;21(7):1525-9
pubmed: 25645861
Int J Mol Sci. 2019 Jan 18;20(2):
pubmed: 30669372
Leuk Res. 2014 Dec;38(12):1460-8
pubmed: 25443888
Hematology. 2017 Oct;22(9):527-535
pubmed: 28395594
Cancer Discov. 2018 Dec;8(12):OF4
pubmed: 30352859
Blood. 1999 Mar 1;93(5):1658-67
pubmed: 10029595
Cell Prolif. 2015 Dec;48(6):682-90
pubmed: 26478515
Cancer Treat Rev. 2015 Dec;41(10):884-92
pubmed: 26342718
Blood. 2000 Feb 1;95(3):846-54
pubmed: 10648395
Oncol Rep. 2014 Jul;32(1):105-14
pubmed: 24840404
Int J Cancer. 2010 Aug 15;127(4):820-9
pubmed: 19998339
Lancet Oncol. 2001 Jul;2(7):437-42
pubmed: 11905738
Blood Cancer J. 2014 Jul 11;4:e228
pubmed: 25014775
Oncotarget. 2017 Jun 28;8(40):67709-67722
pubmed: 28978065
Int J Mol Sci. 2018 Jul 18;19(7):
pubmed: 30021955
Cancer Res. 2006 Jul 15;66(14):7128-35
pubmed: 16854822
Cancer Epidemiol. 2015 Feb;39(1):8-13
pubmed: 25560974
Blood. 2013 Mar 7;121(10):1824-38
pubmed: 23299311
Oncogene. 2000 Sep 7;19(38):4319-27
pubmed: 10980607
N Engl J Med. 2014 Mar 13;370(11):997-1007
pubmed: 24450857
PLoS One. 2013;8(2):e56829
pubmed: 23451095
Leukemia. 2017 Nov;31(11):2388-2397
pubmed: 28757617
Blood. 2009 Oct 15;114(16):3367-75
pubmed: 19636060
Int J Radiat Biol. 2007 Nov-Dec;83(11-12):733-41
pubmed: 17852559
AAPS J. 2011 Jun;13(2):230-9
pubmed: 21387147
Leuk Res. 2014 Aug;38(8):955-63
pubmed: 24974147
Cancer Res. 2003 Nov 15;63(22):7900-6
pubmed: 14633719
Nat Med. 1999 Jun;5(6):662-8
pubmed: 10371505
Biochim Biophys Acta Mol Cell Res. 2019 Nov;1866(11):118522
pubmed: 31394114
J Bone Oncol. 2019 Jul 16;17:100253
pubmed: 31372333
Hematol Oncol. 2021 Feb;39(1):105-113
pubmed: 33078436
Biochim Biophys Acta Mol Cell Res. 2020 May;1867(5):118663
pubmed: 31987794
Oncotarget. 2017 Mar 28;8(13):21650-21662
pubmed: 28423507
Oncol Rep. 2017 Jan;37(1):622-630
pubmed: 27840970
Pediatr Blood Cancer. 2012 Jul 15;59(1):83-9
pubmed: 22183914
Nat Cell Biol. 2002 Apr;4(4):E83-90
pubmed: 11944041
Cell. 1992 Apr 3;69(1):11-25
pubmed: 1555235
Int J Hematol. 2015 Jul;102(1):25-34
pubmed: 25804841
Clin Adv Hematol Oncol. 2014 Dec;12(12 Suppl 20):8-18, 1
pubmed: 25768269
J Biol Chem. 2001 Nov 30;276(48):45380-6
pubmed: 11567031
Cell Rep. 2019 Jan 15;26(3):652-669.e6
pubmed: 30650358
Blood. 2002 Mar 15;99(6):2179-84
pubmed: 11877295
Br J Haematol. 2011 Oct;155(1):53-64
pubmed: 21749361
Leukemia. 2014 Apr;28(4):904-16
pubmed: 23995611
Blood. 2004 Mar 15;103(6):2308-15
pubmed: 14615378
Nat Commun. 2020 Apr 27;11(1):2042
pubmed: 32341362
Tumour Biol. 2016 Jan;37(1):1369-78
pubmed: 26298725
Oncol Rep. 2015 Sep;34(3):1345-52
pubmed: 26134759
Int J Hematol. 2016 Sep;104(3):281-92
pubmed: 27411688
Blood. 2007 Jun 1;109(11):4995-5001
pubmed: 17303695
Blood. 2000 Sep 1;96(5):1926-32
pubmed: 10961896
Mol Med Rep. 2016 Oct;14(4):3759-68
pubmed: 27599538
Mol Cancer Ther. 2010 Oct;9(10):2652-64
pubmed: 20924128
J Physiol Pharmacol. 2020 Aug;71(4):
pubmed: 33214335
Oncotarget. 2016 Sep 13;7(37):60698-60711
pubmed: 27474171
Leuk Lymphoma. 2011 Oct;52(10):1991-8
pubmed: 21718132
Int J Hematol. 2014 Jan;99(1):57-68
pubmed: 24307516
Leuk Res. 2014 Feb;38(2):225-35
pubmed: 24290813
Mol Biol Cell. 2012 Sep;23(17):3473-84
pubmed: 22787275
Clin Cancer Res. 2001 Dec;7(12):4262-71
pubmed: 11751528
Anticancer Res. 2019 Jun;39(6):3033-3038
pubmed: 31177145
Am J Clin Exp Urol. 2019 Aug 15;7(4):297-312
pubmed: 31511835
Blood. 2017 Jul 27;130(4):501-513
pubmed: 28533307
Front Oncol. 2020 Dec 10;10:592733
pubmed: 33425742